Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: D06AX13

Altargo(retapamulin)

Impetigo;Staphylococcal Skin Infections

Marketing Authorisation Holder: Glaxo Group Ltd

EMA Authorisation: 24/05/2007

INN: retapamulin

Indication

Short term treatment of the following superficial skin infections: impetigo; infected small lacerations, abrasions or sutured wounds. See sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of Staphylococcus aureus. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Altargo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.